Viking Therapeutics is trading at $29.90, down -5.17%, mainly amid biotech-sector weakness and risk-off macro conditions.
- No clearly reported negative company-specific catalyst emerged on September 15, 2026.
- Its VK2735 obesity program remains active, with Phase 3 development advancing after approximately 15% weight loss in Phase 2.
- Biotech ETF XBI is down 2.11% during regular trading, amid elevated Treasury yields and Federal Reserve uncertainty.